Cargando…

The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2‐18 years: Results of two phase 3 studies

BACKGROUND: Quadrivalent live attenuated influenza vaccine (Q/LAIV) has not been assessed in Japanese children. OBJECTIVES: Evaluate safety and efficacy of Q/LAIV in Japanese children. PATIENTS/METHODS: Two phase 3 studies were conducted in the 2014‐2015 influenza season. Study 1 was an open‐label,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mallory, Raburn M., Yu, Jing, Kameo, Sachiko, Tanaka, Michio, Rito, Ki, Itoh, Yohji, Dubovsky, Filip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005581/ https://www.ncbi.nlm.nih.gov/pubmed/29573143 http://dx.doi.org/10.1111/irv.12555

Ejemplares similares

Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow‐fill‐seal device in adults: a randomized, active‐controlled study
por: Sheldon, Eric A., et al.
Publicado: (2012)

Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials
por: Mallory, Raburn M., et al.
Publicado: (2010)

1954. A Randomized Study to Evaluate the Shedding and Immunogenicity of H1N1 Strains in Trivalent and Quadrivalent Formulations of FluMist in Children 24 to <48 Months of Age
por: Mallory, Raburn, et al.
Publicado: (2018)

Letter to the editor: Potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines
por: Ambrose, Christopher S, et al.
Publicado: (2016)

1401. Real-World Effectiveness of Inactivated and Live Attenuated Influenza Vaccines in Children During Three Recent Seasons: 2016–2019
por: Bandell, Allyn, et al.
Publicado: (2020)

Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine
por: Wan, Zhimin, et al.
Publicado: (2018)

Live-Attenuated Influenza Vaccine Effectiveness in Children From 2009 to 2015–2016: A Systematic Review and Meta-Analysis
por: Caspard, Herve, et al.
Publicado: (2017)

Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9)
por: Sobhanie, Mahdee, et al.
Publicado: (2016)

Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink
por: Caspard, Herve, et al.
Publicado: (2018)

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model
por: Rudenko, Larisa, et al.
Publicado: (2018)

Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England
por: McNaughton, Rhian, et al.
Publicado: (2016)

No safety signals for GSK quadrivalent influenza vaccine
Publicado: (2022)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) — United States, 2018–19 Influenza Season
por: Grohskopf, Lisa A., et al.
Publicado: (2018)

Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model
por: Gerlier, Laetitia, et al.
Publicado: (2017)

1973. A Meta-Analysis of the Effectiveness of LAIV4 and IIV against Influenza A/H3N2 Strains in Children 2–18 Years of Age During the 2016–2017 Season
por: Mallory, Raburn, et al.
Publicado: (2018)

The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing
por: Ambrose, C. S., et al.
Publicado: (2012)

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18–60 years of age in the Republic of Korea
por: Choi, Won Suk, et al.
Publicado: (2017)

1054 Immunogenicity And Safety of Quadrivalent Influenza Vaccine Administered Intradermally (ID) in Adults 18 through 64 Years of Age
por: Gorse, Geoffrey J., et al.
Publicado: (2014)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
por: Rumi, Filippo, et al.
Publicado: (2023)

Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
por: Tisa, V., et al.
Publicado: (2016)

Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017–2018
por: Boikos, Constantina, et al.
Publicado: (2020)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

Quadrivalent influenza nanoparticle vaccines induce broad protection
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2021)

Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial
por: Sanchez, Leilani, et al.
Publicado: (2019)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control
por: Ray, Riju, et al.
Publicado: (2017)

Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
por: Jamotte, Aurélien, et al.
Publicado: (2016)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
por: Formica, Neil, et al.
Publicado: (2021)

Immune Responses to Circulating and Vaccine Viral Strains in HIV-Infected and Uninfected Children and Youth Who Received the 2013/2014 Quadrivalent Live-Attenuated Influenza Vaccine
por: Weinberg, Adriana, et al.
Publicado: (2016)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Will a Quadrivalent Vaccine Solve the Problem of Influenza B Mismatches?
por: Choi, Eun Hwa, et al.
Publicado: (2018)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v21mogt7gahf8ii33qa89op8ti